Get the Stockscreener App
142.01
2.44%
4.71
After Hours:
142.73
0.72
+0.51%
Belite Bio Inc Adr stock is traded at $142.01, with a volume of 237.24K.
It is up +2.44% in the last 24 hours and down -12.78% over the past month.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
See More
Previous Close:
$137.30
Open:
$137.5
24h Volume:
237.24K
Relative Volume:
1.52
Market Cap:
$5.69B
Revenue:
-
Net Income/Loss:
$-77.61M
P/E Ratio:
-61.80
EPS:
-2.2979
Net Cash Flow:
-
1W Performance:
+0.68%
1M Performance:
-12.78%
6M Performance:
+8.51%
1Y Performance:
+130.58%
1-Day Range:
$134.01
$142.78
1-Week Range:
$134.01
$148.60
52-Week Range:
$56.10
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
142.01 | 5.50B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Initiated | BofA Securities | Buy |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - MSN
Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily
Benchmark reiterates Belite Bio stock rating on drug development progress - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail
Benchmark reiterates Belite Bio stock rating on drug development progress By Investing.com - Investing.com Canada
BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target - TipRanks
H.C. Wainwright reiterates Belite Bio stock rating on NDA progress By Investing.com - Investing.com South Africa
Earnings Scheduled For May 20, 2026 - Sahm
H.C. Wainwright reiterates Belite Bio stock rating on NDA progress - Investing.com
Belite Bio Q1 2026 Earnings Call Transcript - MarketBeat
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses By GuruFocus - Investing.com Canada
BLTE Stock Price, Quote & Chart | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Belite Bio Ramps Toward Tinlarebant Launch - TipRanks
Belite Bio Q1 Earnings Call Highlights - inkl
Belite Bio (BLTE) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Belite Bio beats Q1 2026 EPS estimates, stock dips - Investing.com
Belite Bio Releases Q1 2026 Financial Results - AlphaStreet
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base - TipRanks
Belite Bio Q1 Adjusted Loss Widens - marketscreener.com
Earnings Flash (BLTE) Belite Bio, Inc Posts Q1 Adjusted Loss $0.34 per Share, vs. FactSet Est of $-0.69 - marketscreener.com
Belite Bio stock gains 2% on first-quarter earnings beat By Investing.com - Investing.com Nigeria
Belite Bio stock gains 2% on first-quarter earnings beat - Investing.com
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - Caledonian Record
Belite Bio (NASDAQ: BLTE) starts tinlarebant NDA as Q1 2026 loss deepens - Stock Titan
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewswire Inc.
Belite Bio (BLTE) Is Down 6.6% After Swiss Orphan Status, FDA Filing Progress For Tinlarebant - Sahm
Belite Bio receives Swiss orphan drug status for tinlarebant By Investing.com - Investing.com Nigeria
Belite Bio receives Swiss orphan drug status for tinlarebant - Investing.com
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland - marketscreener.com
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - The Manila Times
Belite Bio (BLTE) CEO & Chairman reports 1.25M shares, including vested awards - Stock Titan
Transcript : Belite Bio, Inc Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03 - marketscreener.com
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results - marketscreener.com
Trading the Move, Not the Narrative: (BLTE) Edition - Stock Traders Daily
Belite Bio (BLTE) CSO exits 666 ADS in 10b5-1 stock sales - Stock Titan
Belite Bio (BLTE) CSO offloads 1,000 ADS in Rule 10b5-1 sales - Stock Titan
Belite Bio (BLTE) CSO sells 1,000 ADSs in Rule 10b5-1 trades - Stock Titan
Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares - Investing.com Nigeria
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS - Stock Titan
Belite Bio CSO Nathan Mata sells $155,777 in shares By Investing.com - Investing.com Australia
Belite Bio CSO Nathan Mata sells $155,777 in shares - Investing.com
Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160 - Stock Titan
Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus - Barchart.com
Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Belite Bio Inc Adr Stock (BLTE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MATA NATHAN L. | Chief Scientific Officer |
May 06 '26 |
Sale |
153.84 |
1,000 |
153,839 |
666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 05 '26 |
Sale |
155.50 |
1,000 |
155,502 |
1,666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 04 '26 |
Sale |
155.64 |
1,000 |
155,636 |
2,666 |
| MATA NATHAN L. | Chief Scientific Officer |
May 01 '26 |
Sale |
155.78 |
1,000 |
155,778 |
3,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 30 '26 |
Sale |
156.97 |
1,000 |
156,973 |
4,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 29 '26 |
Sale |
155.82 |
1,000 |
155,817 |
5,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 28 '26 |
Sale |
159.16 |
1,000 |
159,162 |
6,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 27 '26 |
Sale |
162.64 |
1,000 |
162,641 |
7,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 24 '26 |
Sale |
159.56 |
1,000 |
159,556 |
8,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 23 '26 |
Sale |
166.28 |
1,000 |
166,284 |
9,666 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):